POST Online Media Lite Edition



 

Roche's $4.3 billion Spark bid delayed again as FTC wants more data

Christian Fernsby |
Roche’s $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again as regulators continue to scrutinize the deal for its effect on competition.

Article continues below




Roche said on Monday that both companies received a request for more information from the U.S. Federal Trade Commission in connection with the FTC’s review of the deal.

Roche also said that the UK Competition and Markets Authority (CMA) has opened an investigation.

Roche wants to buy Spark to, among other things, get ahold of U.S. firm’s experimental gene therapy for hemophilia A as well as its platform to develop other treatments for genetic diseases. But Roche has been forced to push back completion repeatedly, this time giving itself to July 31, beyond its self-imposed first-half deadline, to wrap things up.


What to read next

Roche and Genentech announce organizational and leadership changes
Highlights: February 25 - March 2, 2019
Roche enters strategic collaboration with Foundation Medicine